

# COVAX Reminder: 4 February 2022

## Key Date for AMC Participants to provide vaccine demand



19 January 2022

From: COVAX

To: Participant Country Governments

Re: DEMAND FORECAST FOR COVID-19 VACCINES 2022-23

**Context**

The overall COVID-19 vaccine situation has evolved during 2021, moving from supply constraints and high demand to having a diversified supplier base with increasingly reliable supply. To support countries in meeting their vaccine coverage targets, COVAX will evolve in 2022 to an allocation model primarily driven by the forecasted needs received from countries.

To enable this, the COVAX Country Readiness and Delivery Team is implementing a reformed Demand Forecasting & Planning process for all AMC countries. The aims of this process are:

- To increase the maturity of country-level demand data, allowing it to become the driving feature of the COVAX allocation process, while continuing to take product availability into account.
- To increase the planning horizon of dose allocations and shipments and improve the ability of COVAX to inform manufacturers of country needs ahead of time.

**Supporting materials**

Alongside this letter, your GAVI Senior Country Manager and/or UNICEF Country Office will provide two documents that will enable this updated approach:

1. First, we are pleased to share a new template for capturing Country Demand Forecasts. Currently an Excel spreadsheet, this document will allow countries to provide a more mature demand forecast, over time and by product, than has previously been possible. This template does not replace the information countries provide on the Country Collaboration Platform (CCP). In due course, these two will be merged. Until then, countries are requested to continue completing the information in the CCP alongside this more detailed template.
2. COVAX staff will also share the latest shipment forecast for your country across all COVAX products and completed allocation rounds.

**Request to countries**

Countries are politely requested to review the documents and then to initiate the forecast process with their GAVI SCM and UNICEF/PAHO Country Office. The forecast is expected to consider the country's vaccinator

When completing the forecast, we will be able to allow changing country COVAX allocation requests. Please note that we guarantee allocation



FORCAST FOR COVID-19 Vaccines

COUNTRY: [ ]  
 ISSUED BY (if applicable): [ ]  
 REVIEWED BY (if any): NAME & EMAIL: [ ]  
 REVIEWED BY (if any): NAME & EMAIL: [ ]  
 FORECAST SUBMISSION COMPLETED (YYYY-MM-DD): [ ]

Table 1: Coverage target

Country	Coverage target in % of the population	Expected date of coverage

Table 2: COVAX Facility (The first 6 months of forecast are the most critical to inform off)

Manufacturer	Vaccine name	Cold Chain requirements	Date of Release	Monthly Forecast														
				Jan-22	Feb-22	Mar-22	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22			
AstraZeneca AB	COVID-19	UC	Some															
Moderna	COVID-19	UC	Some															
Novartis	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															
Novartis (MAB)	COVID-19	UC	Some															

- **What's needed?** 6-month forecast of COVID-19 vaccine supply requirements – including product preferences
- **Why?** updated country demand data is critical for next major COVAX Allocation Round (aims to cover 6 months of supply)
- **How?** using Excel template shared in mid-January. Support available from WHO & Unicef Country Offices & Gavi teams

**NOTE:** this is a key part of the ongoing work between COVAX partners & countries to update demand projections on a monthly basis with focused support to countries facing challenges in absorption, stock levels, or funding